Voyager Q4 2025 net loss $27.4M, cash $201.7M; key pipeline milestones H2 2026

Voyager Therapeutics, Inc.

Q4 2025 net loss $27.4M vs $34.5M in Q4 2024; full year net loss $119.7M vs $65.0M.
Collaboration revenue Q4 $15.3M (up 143% YoY) but full year $40.4M (down 50% YoY).
Cash $201.7M at Dec 31 2025; runway expected into 2028 with up to $2.4B in milestone potential.
VY1706 (tau-silencing) IND planned Q2 2026, first-in-human dosing H2 2026; VY7523 tau PET data H2 2026.
APOE gene therapy program paused; Neurocrine milestone $3M triggered in Q4 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Voyager Therapeutics, Inc. reported the year ended December 31, 2025 results: revenue $40.4 million, net income $119.7 million.

Period: the year ended December 31, 2025
Revenue: $40.4 million
Net income: $119.7 million
Result: reported results

Exact text from the filing

● Collaboration Revenues: Collaboration revenue was $15.3 million for the three months ended December 31, 2025, compared to $6.3 million for the same period in 2024 , and $40.4 million for the year ended December 31, 2025, compared to $80.0 million for the same period in 2024. The increase for the three months ended December 31, 2025, was primarily due to

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Voyager Therapeutics, Inc. reported the three months ended December 31, 2025 results: revenue $15.3 million, net income $27.4 million.

Period: the three months ended December 31, 2025
Revenue: $15.3 million
Net income: $27.4 million
Result: reported results

Exact text from the filing

intends to initiate a clinical trial with NBIB-‘223 for FA, pending successful FDA IND clearance Financial Results ● Collaboration Revenues: Collaboration revenue was $15.3 million for the three months ended December 31, 2025, compared to $6.3 million for the same period in 2024 , and $40.4 million for the year ended December 31, 2025, compared to $80.0

View on SEC.gov

Browse all earnings releases →

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-025201

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.